Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 50 articles:
HTML format



Single Articles


    December 2024
  1. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    PubMed     Abstract available


    November 2024
  2. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
    SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
    Cancer Lett. 2024;605:217282.
    PubMed     Abstract available


  3. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
    Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
    Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
    PubMed     Abstract available


    October 2024
  4. NING Y, Chen Y, Tian T, Gao X, et al
    S100A7 Orchestrates Neutrophil Chemotaxis and Drives Neutrophil Extracellular Traps (NETs) Formation to Facilitate Lymph Node Metastasis in Cervical Cancer Patients.
    Cancer Lett. 2024 Oct 7:217288. doi: 10.1016/j.canlet.2024.217288.
    PubMed     Abstract available


    September 2024
  5. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    PubMed     Abstract available


    August 2024
  6. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    PubMed     Abstract available


    July 2024
  7. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    PubMed     Abstract available


  8. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    PubMed     Abstract available


    June 2024
  9. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    PubMed     Abstract available


  10. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    PubMed     Abstract available


  11. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    PubMed     Abstract available


    April 2024
  12. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed     Abstract available


  13. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    PubMed     Abstract available


    March 2024
  14. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    PubMed     Abstract available


  15. CAO C, Xu Q, Zhu Z, Xu M, et al
    Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
    Cancer Lett. 2024 Mar 10:216809. doi: 10.1016/j.canlet.2024.216809.
    PubMed     Abstract available


    February 2024
  16. LIU J, Liu C, Ma Y, Pan X, et al
    STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
    Cancer Lett. 2024 Feb 17:216700. doi: 10.1016/j.canlet.2024.216700.
    PubMed     Abstract available


    January 2024
  17. AO K, Yin M, Lyu X, Xiao Y, et al
    METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer.
    Cancer Lett. 2024 Jan 20:216658. doi: 10.1016/j.canlet.2024.216658.
    PubMed     Abstract available


  18. MEI X, Xiong J, Liu J, Huang A, et al
    DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion.
    Cancer Lett. 2024 Jan 9:216609. doi: 10.1016/j.canlet.2024.216609.
    PubMed     Abstract available


    December 2023
  19. LIN CL, Ying TH, Yang SF, Lin CL, et al
    Magnolin targeting of the JNK/Sp1/MMP15 signaling axis suppresses cervical cancer microenvironment and metastasis via microbiota modulation.
    Cancer Lett. 2023 Dec 18:216584. doi: 10.1016/j.canlet.2023.216584.
    PubMed     Abstract available


    November 2023
  20. NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al
    Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
    Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509.
    PubMed     Abstract available


  21. GARG V, Kumar L
    Metronomic chemotherapy in ovarian cancer.
    Cancer Lett. 2023 Nov 1:216469. doi: 10.1016/j.canlet.2023.216469.
    PubMed     Abstract available


    October 2023
  22. CHEN L, Zheng X, Liu W, Sun Y, et al
    Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer.
    Cancer Lett. 2023 Oct 20:216445. doi: 10.1016/j.canlet.2023.216445.
    PubMed     Abstract available


  23. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
    Cancer Lett. 2023 Oct 12:216437. doi: 10.1016/j.canlet.2023.216437.
    PubMed     Abstract available


    September 2023
  24. YUE S, Wang Q, Zhang J, Hu Q, et al
    Understanding cervical cancer at single-cell resolution.
    Cancer Lett. 2023 Sep 26:216408. doi: 10.1016/j.canlet.2023.216408.
    PubMed     Abstract available


  25. VENKATA PP, Jayamohan S, He Y, Alejo S, et al
    Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Cancer Lett. 2023 Sep 13:216383. doi: 10.1016/j.canlet.2023.216383.
    PubMed     Abstract available


    August 2023
  26. ZHANG X, Guo H, Chen J, Xu C, et al
    Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Cancer Lett. 2023 Aug 17:216355. doi: 10.1016/j.canlet.2023.216355.
    PubMed     Abstract available


    July 2023
  27. BERTAGNIN C, Messa L, Pavan M, Celegato M, et al
    A small molecule targeting the interaction between human papillomavirus E7 oncoprotein and cellular phosphatase PTPN14 exerts antitumoral activity in cervical cancer cells.
    Cancer Lett. 2023 Jul 31:216331. doi: 10.1016/j.canlet.2023.216331.
    PubMed     Abstract available


  28. POOREBRAHIM M, Quiros-Fernandez I, Marme F, Burdach SE, et al
    A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
    Cancer Lett. 2023;566:216242.
    PubMed     Abstract available


  29. CHEN X, Zhou J, Li X, Wang X, et al
    Corrigendum to "Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype" [Cancer Lett. 435 (28 October 2018) 80-91].
    Cancer Lett. 2023 Jul 8:216292. doi: 10.1016/j.canlet.2023.216292.
    PubMed    


    May 2023
  30. SHAO Y, Li H, Wu Y, Wang X, et al
    The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer.
    Cancer Lett. 2023;565:216241.
    PubMed     Abstract available


    April 2023
  31. MOSKOVICH D, Alfandari A, Finkelshtein Y, Weisz A, et al
    Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Cancer Lett. 2023;563:216196.
    PubMed    


    January 2023
  32. ZHANG Y, Qiu JG, Jia XY, Ke Y, et al
    METTL3-mediated N6-methyladenosine modification and HDAC5/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance.
    Cancer Lett. 2023;553:215971.
    PubMed     Abstract available


  33. JIANG W, Ouyang X, Ji Z, Shi W, et al
    The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.
    Cancer Lett. 2023;556:216064.
    PubMed     Abstract available


  34. HOLLIS RL
    Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
    Cancer Lett. 2023;555:216057.
    PubMed     Abstract available


    September 2022
  35. ZHANG YR, Zheng PS
    NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes.
    Cancer Lett. 2022 Sep 14:215917. doi: 10.1016/j.canlet.2022.215917.
    PubMed     Abstract available


    August 2022
  36. XIANG T, Du L, Pham P, Zhu B, et al
    Corrigendum to "Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway" [Cancer Letters 364 (2015) 79-88].
    Cancer Lett. 2022 Aug 25:215895. doi: 10.1016/j.canlet.2022.215895.
    PubMed    


    June 2022
  37. RUSSO A, Zizhao Y, Heyrman GM, Cain BP, et al
    Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
    Cancer Lett. 2022 Jun 10:215779. doi: 10.1016/j.canlet.2022.215779.
    PubMed     Abstract available


    May 2022
  38. WANG W, Jo H, Park S, Kim H, et al
    Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer.
    Cancer Lett. 2022 May 12:215735. doi: 10.1016/j.canlet.2022.215735.
    PubMed     Abstract available


    April 2022
  39. ZHAO Z, Shuang T, Gao Y, Lu F, et al
    Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.
    Cancer Lett. 2022;530:45-58.
    PubMed     Abstract available


    January 2022
  40. SOTO-GAMEZ A, Wang Y, Zhou X, Seras L, et al
    Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
    Cancer Lett. 2022;525:67-75.
    PubMed     Abstract available


  41. DU S, Qian J, Tan S, Li W, et al
    Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer.
    Cancer Lett. 2022;529:168-179.
    PubMed     Abstract available


  42. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed     Abstract available


    December 2021
  43. ZHAN L, Zhang J, Zhang J, Liu X, et al
    LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
    Cancer Lett. 2021;529:37-52.
    PubMed     Abstract available


  44. QIAO HY, Zhang Q, Wang JM, Jiang JY, et al
    TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
    Cancer Lett. 2021;529:85-99.
    PubMed     Abstract available


  45. SALINAS-MONTALVO AM, Supramaniam A, McMillan NA, Idris A, et al
    RNA-based gene targeting therapies for human papillomavirus driven cancers.
    Cancer Lett. 2021;523:111-120.
    PubMed     Abstract available


  46. LIU C, Huang Y, Qin T, You L, et al
    AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
    Cancer Lett. 2021 Dec 20. pii: S0304-3835(21)00638.
    PubMed     Abstract available


    November 2021
  47. SUN D, Qin Z, Xu Y, Xiao Q, et al
    The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation.
    Cancer Lett. 2021 Nov 11. pii: S0304-3835(21)00569.
    PubMed     Abstract available


  48. PIN F, Prideaux M, Huot JR, Essex AL, et al
    Non-bone metastatic cancers promote osteocyte-induced bone destruction.
    Cancer Lett. 2021;520:80-90.
    PubMed     Abstract available


    October 2021
  49. ZHAO S, Huang L, Basu P, Domingo EJ, et al
    Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries.
    Cancer Lett. 2021;525:22-32.
    PubMed     Abstract available


  50. VENKATA PP, Chen Y, Alejo S, He Y, et al
    KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
    Cancer Lett. 2021;524:219-231.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.